View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 30, 2018updated 12 Jul 2022 1:12pm

Impel doses first subject in Phase l trial of INP105

Impel NeuroPharma has dosed the first subject in the Phase l Safety and Tolerability of Intranasal POD-olanzapine (SNAP 101) trial of INP105 for the treatment of acute agitation in bipolar I disorder and schizophrenia.

Impel NeuroPharma has dosed the first subject in the Phase l Safety and Tolerability of Intranasal POD-olanzapine (SNAP 101) trial of INP105 for the treatment of acute agitation in bipolar I disorder and schizophrenia.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The randomised, double-blind, placebo-and-active controlled crossover trial is designed to evaluate the safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) of INP105 in 36 healthy subjects.

During the study, three ascending doses of INP105 will be delivered to compare them with two doses of Zyprexa intramuscular and orally disintegrating Zyprexa Zydis.

Impel will use its precision olfactory delivery (POD) device for intranasal delivery of INP105 to the subjects.

The SNAP 101 trial intends to establish the safety and tolerability of INP105, as well as provide the appropriate dosing for future studies of INP105’s PK and PD profiles.

“The evolution of mental healthcare options and treatments in the US is a priority, and there is a specific unmet need for optimal treatments that could address acute agitation.”

Impel NeuroPharma CEO Jon Congleton said: “The evolution of mental healthcare options and treatments in the US is a priority, and there is a specific unmet need for optimal treatments that could address acute agitation.

“Our goal with INP105 is to provide an easy-to-administer, rapidly acting medicine that addresses acute agitation with a therapy that can be used in both the hospital and home setting without an injection.”

Acute agitation is described as excessive motor activity related to a feeling of inner tension, often arises from serious underlying mental health conditions such as bipolar I disorder or schizophrenia.

Approximately 1.7 million to seven million episodes of acute agitation have been reported, or estimated, to happen in US hospitals annually.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena